SCHEMBL4724201

SCHEMBL4724201

CCOc1c(-c2ccccc2)[c]nc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
MEN1 O00255 2/20 0.40
ELANE P08246 1/20 0.39
MAPT P10636 4/20 0.39
POLB P06746 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 2/20 0.38
KDM4E B2RXH2 3/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
RAD52 P43351 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GLA P06280 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GUSB P08236 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724169 0.88 MAPT (0.40) KMT2AMEN1MAPTPOLBHPGD
SCHEMBL4723585 0.87 L3MBTL1 (0.40) MAPTL3MBTL1HPGDSMN1; SMN2TP53
SCHEMBL577791 0.83 POLB (0.55) KMT2AMAPTPOLBL3MBTL1HPGD
SCHEMBL4719855 0.80 KMT2A (0.41) KMT2AMEN1ELANEMAPTPOLB
SCHEMBL29488275 0.75 POLB (0.61) KMT2AMEN1ELANEMAPTPOLB
SCHEMBL3349292 0.75 POLB (0.61) KMT2AMEN1ELANEMAPTPOLB
SCHEMBL4721248 0.70 TLR8 (0.37) KMT2AMEN1MAPTPOLBL3MBTL1
SCHEMBL28620478 0.69 KMT2A (0.51) KMT2AMEN1ELANEMAPTPOLB
SCHEMBL4720694 0.69 L3MBTL1 (0.40) L3MBTL1ALDH1A1SLC2A1GAALMNA
Ammonia Solution, Strong SCHEMBL2417496 0.68 ELANE (0.46) KMT2AMEN1ELANEMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 KMT2A 3345/4885MEN1 4451/4885ELANE 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.